Cargando…

Long‐term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52‐week, open‐label, multicentre phase 3 trial

AIM: To evaluate the safety and efficacy of imeglimin for 52 weeks as monotherapy or combination therapy with existing antidiabetic agents in Japanese patients with type 2 diabetes. MATERIALS AND METHODS: TIMES 2 was a phase 3, pivotal, open‐label trial including patients with type 2 diabetes inadeq...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dubourg, Julie, Fouqueray, Pascale, Quinslot, Damien, Grouin, Jean‐Marie, Kaku, Kohei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305103/ https://www.ncbi.nlm.nih.gov/pubmed/34866306 http://dx.doi.org/10.1111/dom.14613

Ejemplares similares

Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24‐week, randomized, double‐blind, placebo‐controlled, dose‐ranging phase 2b trial
por: Dubourg, Julie, et al.
Publicado: (2021)

Efficacy and safety of imeglimin add‐on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double‐blind, placebo‐controlled phase 3 trial with a 36‐week open‐label extension period
por: Reilhac, Caroline, et al.
Publicado: (2022)

Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects
por: Fouqueray, Pascale, et al.
Publicado: (2022)

The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
por: Fouqueray, Pascale, et al.
Publicado: (2013)

Long‐term safety and efficacy of a novel once‐weekly oral trelagliptin as monotherapy or in combination with an existing oral antidiabetic drug in patients with type 2 diabetes mellitus: A 52‐week open‐label, phase 3 study
por: Inagaki, Nobuya, et al.
Publicado: (2016)

Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes
por: Hallakou‐Bozec, Sophie, et al.
Publicado: (2020)

Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin
por: Theurey, Pierre, et al.
Publicado: (2022)

Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity
por: Theurey, Pierre, et al.
Publicado: (2022)

Effect of patient characteristics on the efficacy and safety of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus: A post‐hoc analysis of two randomized, placebo‐controlled trials
por: Hagi, Katsuhiko, et al.
Publicado: (2023)

Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action
por: Hallakou-Bozec, Sophie, et al.
Publicado: (2021)

Development of Imeglimin Electrospun Nanofibers as a Potential Buccal Antidiabetic Therapeutic Approach
por: Alamer, Ali A., et al.
Publicado: (2023)

Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: A randomized, 52‐week, open‐label, parallel‐group trial
por: Kaku, Kohei, et al.
Publicado: (2015)

Effects of the anti-diabetic imeglimin in hyperglycemic mice with septic shock
por: Wagner, F, et al.
Publicado: (2012)

Efficacy, safety and tolerability of imeglimin in patients with type 2 diabetes mellitus: A meta‐analysis of randomized controlled trials
por: Hagi, Katsuhiko, et al.
Publicado: (2023)

Glucagon‐like peptide‐1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52‐week, randomized, multicenter trial
por: Seino, Yutaka, et al.
Publicado: (2011)

Safety and efficacy of the combination of the glucagon‐like peptide‐1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post‐hoc analysis of a randomized, 52‐week, open‐label, parallel‐group trial
por: Kiyosue, Arihiro, et al.
Publicado: (2017)

Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration
por: Detaille, D, et al.
Publicado: (2016)

A Multicentre, Multinational, Open-Label, 52-Week Extension Study of Gemigliptin (LC15-0444) Monotherapy in Patients with Type 2 Diabetes Mellitus
por: Yang, Sae Jeong, et al.
Publicado: (2021)

Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks
por: Kadowaki, Takashi, et al.
Publicado: (2012)

Stimulatory effect of imeglimin on incretin secretion
por: Yingyue, Quan, et al.
Publicado: (2023)

Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study
por: Fouqueray, Pascale, et al.
Publicado: (2021)

Safety and efficacy of once‐weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial
por: Kaku, Kohei, et al.
Publicado: (2018)

Imeglimin exerts favorable effects on pancreatic β-cells by improving morphology in mitochondria and increasing the number of insulin granules
por: Sanada, Junpei, et al.
Publicado: (2022)

Long‐term safety and efficacy of tofogliflozin as add‐on to insulin in patients with type 2 diabetes: Results from a 52‐week, multicentre, randomized, double‐blind, open‐label extension, Phase 4 study in Japan (J‐STEP/INS)
por: Terauchi, Yasuo, et al.
Publicado: (2018)

Remission of hyperglycemia after withdrawal of oral antidiabetic drugs in Japanese patients with early‐stage type 2 diabetes
por: Hirukawa, Hidenori, et al.
Publicado: (2018)

Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes
por: Vuylsteke, Valerie, et al.
Publicado: (2015)

Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes
por: Tomita, Yoshiko, et al.
Publicado: (2022)

Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial
por: Kondo, Yaeko, et al.
Publicado: (2016)

Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus
por: Onishi, Yukiko, et al.
Publicado: (2012)

Molecular Mechanisms by Which Imeglimin Improves Glucose Homeostasis
por: Yaribeygi, Habib, et al.
Publicado: (2020)

Long‐term (52‐week) efficacy and safety of ipragliflozin add‐on therapy to insulin in Japanese patients with type 1 diabetes mellitus: An uncontrolled, open‐label extension of a phase III study
por: Kaku, Kohei, et al.
Publicado: (2020)

Imeglimin preserves islet β‐cell mass in Type 2 diabetic ZDF rats
por: Hallakou‐Bozec, Sophie, et al.
Publicado: (2020)

The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cells
por: Vial, Guillaume, et al.
Publicado: (2021)

Imeglimin‐mediated glycemic control in maternally inherited deafness and diabetes
por: Ishibashi, Ryoichi, et al.
Publicado: (2023)

Potential Ketoacidosis Linked to Imeglimin and Metformin Co-administration in a Patient With Type 2 Diabetes
por: Yamagishi, Hirofumi, et al.
Publicado: (2023)

Long-term Effects of Mitiglinide in Japanese Diabetics Inadequately Controlled with DPP-4 Inhibitor or Biguanide Monotherapy
por: Kaku, Kohei, et al.
Publicado: (2014)

Dapagliflozin as Monotherapy or Combination Therapy in Japanese Patients with Type 2 Diabetes: an Open-Label Study
por: Kaku, Kohei, et al.
Publicado: (2014)

What Is the Optimal Monotherapy in Korean Drug-Naïve Type 2 Diabetic Patients?: The Practical Evidence of Antidiabetic Monotherapy Study
por: Choi, Ji Hun, et al.
Publicado: (2011)

Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus
por: Seino, Yutaka, et al.
Publicado: (2015)

Effects of imeglimin on mitochondrial function, AMPK activity, and gene expression in hepatocytes
por: Hozumi, Kaori, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fhfv4qf93da8385es749pqe7a2